NO2009005I2 - - Google Patents

Info

Publication number
NO2009005I2
NO2009005I2 NO2009005C NO2009005C NO2009005I2 NO 2009005 I2 NO2009005 I2 NO 2009005I2 NO 2009005 C NO2009005 C NO 2009005C NO 2009005 C NO2009005 C NO 2009005C NO 2009005 I2 NO2009005 I2 NO 2009005I2
Authority
NO
Norway
Application number
NO2009005C
Other languages
Norwegian (no)
Other versions
NO2009005I1 (no
Original Assignee
Roche Palo Alto Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26796494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2009005(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Palo Alto Llc filed Critical Roche Palo Alto Llc
Publication of NO2009005I1 publication Critical patent/NO2009005I1/no
Publication of NO2009005I2 publication Critical patent/NO2009005I2/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
NO2009005C 1998-09-10 2009-03-05 Ranolazin samt salter og solvater derav NO2009005I1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9980498P 1998-09-10 1998-09-10
US09/321,522 US6303607B1 (en) 1998-09-10 1999-05-27 Method for administering a sustained release ranolanolazine formulation
PCT/US1999/020967 WO2000013686A2 (en) 1998-09-10 1999-09-09 Sustained release ranolazine formulations

Publications (2)

Publication Number Publication Date
NO2009005I1 NO2009005I1 (no) 2009-03-16
NO2009005I2 true NO2009005I2 (en, 2012) 2010-06-28

Family

ID=26796494

Family Applications (4)

Application Number Title Priority Date Filing Date
NO20011191A NO319434B1 (no) 1998-09-10 2001-03-08 Farmasoytisk oral doseform av ranolazin-preparater med depotvirkning og en komprimert tablett.
NO20011192A NO320986B1 (no) 1998-09-10 2001-03-08 Anvendelse av ranolazin og minst ett pH-avhengig bindemiddel for fremstilling av ranolazinpreparater med depotvirkning
NO20054324A NO20054324L (no) 1998-09-10 2005-09-20 Anvendelse av ranolazin og minst ett pH-avhengig bindemiddel for fremstilling av ranolazinpreparater med depotvirkning
NO2009005C NO2009005I1 (no) 1998-09-10 2009-03-05 Ranolazin samt salter og solvater derav

Family Applications Before (3)

Application Number Title Priority Date Filing Date
NO20011191A NO319434B1 (no) 1998-09-10 2001-03-08 Farmasoytisk oral doseform av ranolazin-preparater med depotvirkning og en komprimert tablett.
NO20011192A NO320986B1 (no) 1998-09-10 2001-03-08 Anvendelse av ranolazin og minst ett pH-avhengig bindemiddel for fremstilling av ranolazinpreparater med depotvirkning
NO20054324A NO20054324L (no) 1998-09-10 2005-09-20 Anvendelse av ranolazin og minst ett pH-avhengig bindemiddel for fremstilling av ranolazinpreparater med depotvirkning

Country Status (33)

Country Link
US (14) US6303607B1 (en, 2012)
EP (3) EP1109558B1 (en, 2012)
JP (2) JP3745621B2 (en, 2012)
KR (1) KR100475759B1 (en, 2012)
CN (2) CN1193757C (en, 2012)
AR (3) AR022085A1 (en, 2012)
AT (2) ATE285774T1 (en, 2012)
AU (4) AU760435B2 (en, 2012)
BR (2) BR9913626A (en, 2012)
CA (2) CA2342390C (en, 2012)
CY (1) CY2008020I2 (en, 2012)
CZ (2) CZ301375B6 (en, 2012)
DE (3) DE69901570T2 (en, 2012)
DK (2) DK1096937T3 (en, 2012)
ES (2) ES2234302T3 (en, 2012)
FR (1) FR09C0001I2 (en, 2012)
GE (1) GEP20053420B (en, 2012)
HK (1) HK1044284B (en, 2012)
HU (2) HU224215B1 (en, 2012)
IL (6) IL141893A0 (en, 2012)
LU (1) LU91504I2 (en, 2012)
MX (2) MXPA01002598A (en, 2012)
NL (1) NL300371I2 (en, 2012)
NO (4) NO319434B1 (en, 2012)
NZ (2) NZ510384A (en, 2012)
PL (3) PL196668B1 (en, 2012)
PT (2) PT1096937E (en, 2012)
RU (2) RU2207856C2 (en, 2012)
SI (2) SI1109558T1 (en, 2012)
TR (2) TR200101262T2 (en, 2012)
TW (1) TWI241911B (en, 2012)
UA (2) UA75027C2 (en, 2012)
WO (2) WO2000013686A2 (en, 2012)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
CN1227004C (zh) * 2000-02-18 2005-11-16 Cv治疗公司 治疗充血性心力衰竭的部分脂肪酸氧化抑制剂
AU2001277938A1 (en) * 2000-07-21 2002-02-05 Cv Therapeutics, Inc. Method for treating angina
AU2001211213A1 (en) * 2000-10-20 2002-04-29 Galephar M/F Stable oral formulation containing benzimidazole derivative
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US20080109040A1 (en) * 2002-04-04 2008-05-08 Luiz Belardinelli Method of treating arrhythmias
ES2320438T7 (es) 2002-04-09 2013-02-14 Flamel Technologies Formulación farmaceútica oral de suspensión acuosa de microcápsulas que permiten la liberación modificada de principio(s) activo(s)
EP1492531B3 (fr) * 2002-04-09 2012-04-11 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiée d'amoxicilline
CN100551370C (zh) 2002-05-21 2009-10-21 Cv医药有限公司 雷诺嗪在制备治疗糖尿病的药物组合物中的应用
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
GB0403098D0 (en) 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
UA90875C2 (ru) * 2005-01-06 2010-06-10 СиВи СЕРАПЬЮТИКС, ИНК. Лекарственные формы пролонгированного действия, которые содержат ранолазин
FR2886150B1 (fr) * 2005-05-24 2007-08-24 Flamel Technologies Sa Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique
CA2616845A1 (en) * 2005-07-28 2007-02-08 Supernus Pharmaceuticals, Inc. Modified release tablet formulations with enhanced mechanical properties
US20090091253A1 (en) * 2006-03-17 2009-04-09 Konica Minolta Holdings, Inc. Organic electroluminescent element, display device and lighting device
FI20060501L (fi) * 2006-05-22 2007-11-23 Biohit Oyj Koostumus ja menetelmä asetaldehydin sitomiseksi vatsassa
EP2117549A1 (en) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Use of ranolazine for the treatment of coronary microvascular diseases
US20090312340A1 (en) * 2007-02-13 2009-12-17 Whedy Wang Use of ranolazine for the treatment of cardiovascular diseases
EP2216024A3 (en) 2007-02-13 2011-08-24 Cv Therapeutics, Inc. Use of Ranolazine for the treatment of cardiovascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
US20080193530A1 (en) * 2007-02-13 2008-08-14 Brent Blackburn Use of ranolazine for the treatment of non-coronary microvascular diseases
EP2139877B1 (en) * 2007-03-07 2011-05-11 Concert Pharmaceuticals Inc. Deuterated piperazine derivatives as anti-anginal compounds
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
RU2442585C2 (ru) * 2007-05-31 2012-02-20 Си Ви Терапьютикс, Инк. Способ лечения диабета
EA200971073A1 (ru) * 2007-05-31 2010-08-30 Джилид Пало Альто, Инк. Применение ранолазина при повышенном уровне натрийуретического пептида мозгового типа
CN101066253B (zh) * 2007-06-07 2011-01-05 北京本草天源药物研究院 一种雷诺嗪缓释片
US20080312247A1 (en) * 2007-06-13 2008-12-18 Auspex Pharmaceuticals, Inc. Substituted piperazines
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
US20090076018A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched ranolazine
WO2009100380A1 (en) * 2008-02-06 2009-08-13 Cv Therapeutics, Inc. Use of ranolazine for treating pain
US20100292217A1 (en) * 2009-05-14 2010-11-18 Gilead Palo Alto, Inc. Ranolazine for the treatment of cns disorders
US8901128B2 (en) 2009-05-28 2014-12-02 Lupin Limited Pharmaceutical compositions of ranolazine
EP2480234B1 (en) * 2009-09-25 2020-02-26 Lupin Limited Sustained release composition of ranolazine
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
TW201215392A (en) 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension
EP2524688B1 (en) 2011-05-11 2013-05-01 ratiopharm GmbH Composition for modified release comprising ranolazine
NO3175985T3 (en, 2012) 2011-07-01 2018-04-28
EP2758053A1 (en) 2011-09-21 2014-07-30 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
US20160305924A1 (en) * 2013-04-26 2016-10-20 Laguna Pharmaceuticals , Inc. Methods for calibrating the administration of vanoxerine for terminating acute episodes of cardiac arrhythmia, restoring normal sinus rhythm, preventing recurrence of cardiac arrhythmia and maintaining normal sinus rhythm in mammals
CN104758265B (zh) * 2014-01-07 2019-05-17 四川海思科制药有限公司 一种雷诺嗪缓释片药物组合物及其制备方法
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
TW201717919A (zh) 2015-07-02 2017-06-01 國際藥品股份公司 雷諾多重壓縮錠劑
WO2018001582A1 (en) 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets
AR110252A1 (es) 2016-11-30 2019-03-13 Gilead Sciences Inc Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
US10898444B2 (en) 2017-06-01 2021-01-26 Sun Pharmaceutical Industries Limited Extended release multiparticulates of ranolazine
CN112438955A (zh) * 2019-08-30 2021-03-05 深圳翰宇药业股份有限公司 一种雷诺嗪缓释组合物及其制备方法
JP2023507626A (ja) 2019-12-16 2023-02-24 テナックス・セラピューティクス，インコーポレイテッド 駆出率が保たれた心不全を伴う肺高血圧症（ＰＨ－ＨＦ－ｐＥＦ）を治療するためのレボシメンダン
CN110898024A (zh) * 2019-12-17 2020-03-24 卓和药业集团有限公司 一种治疗心绞痛的药物组合物及制备方法
GR1010345B (el) * 2021-12-16 2022-11-28 Φαρματεν Α.Β.Ε.Ε., Δισκια παρατεταμενης αποδεσμευσης που περιλαμβανουν ρανολαζινη και μεθοδος παραγωγης αυτων
WO2023130028A1 (en) 2021-12-31 2023-07-06 Tenax Therapeutics, Inc. Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction
GR1010510B (el) * 2022-06-07 2023-07-20 Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, Στερεες φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης ρανολαζινης

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
IL81419A0 (en) * 1986-01-30 1987-08-31 Syntex Inc Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation
ES2182863T3 (es) * 1989-06-23 2003-03-16 Syntex Llc Ranolazina y piperazinas relacionadas para proteger musculos esqueleticos.
US5527545A (en) 1989-09-18 1996-06-18 Recordati S.A. Chemical And Pharmaceutical Company Liquid-suspension controlled-release pharmaceutical composition
US5209933A (en) * 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
JP2516524B2 (ja) * 1992-04-27 1996-07-24 大洋薬品工業株式会社 持続性製剤
JPH06199657A (ja) * 1992-12-10 1994-07-19 Sumitomo Pharmaceut Co Ltd 徐放性製剤
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
JPH07112932A (ja) * 1993-08-27 1995-05-02 Mitsui Toatsu Chem Inc 徐放性医薬製剤
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
JPH08259446A (ja) * 1995-01-24 1996-10-08 Mitsui Toatsu Chem Inc 持効性医薬製剤
JPH08310946A (ja) * 1995-05-19 1996-11-26 Yuutoku Yakuhin Kogyo Kk 経皮吸収製剤
JPH09188617A (ja) * 1996-01-08 1997-07-22 Pola Chem Ind Inc 徐放性医薬組成物
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine

Also Published As

Publication number Publication date
DE69901570T2 (de) 2003-01-09
NO320986B1 (no) 2006-02-20
CZ2001879A3 (cs) 2001-08-15
US6369062B1 (en) 2002-04-09
EP1096937B9 (en) 2007-02-28
US6562826B1 (en) 2003-05-13
IL175371A0 (en) 2006-09-05
PL348249A1 (en) 2002-05-20
US6852724B2 (en) 2005-02-08
AU744071B2 (en) 2002-02-14
CZ2001880A3 (cs) 2001-08-15
KR20010089874A (ko) 2001-10-12
CN1193757C (zh) 2005-03-23
DE69922964D1 (de) 2005-02-03
DK1096937T3 (da) 2005-05-09
AU2008207707A1 (en) 2008-09-25
US20040029890A1 (en) 2004-02-12
AR052921A1 (es) 2007-04-11
NO20011191L (no) 2001-04-30
GEP20053420B (en) 2005-01-25
IL141893A0 (en) 2002-03-10
KR100475759B1 (ko) 2005-03-10
PL196668B1 (pl) 2008-01-31
US6864258B2 (en) 2005-03-08
CZ301375B6 (cs) 2010-02-03
HK1044284A1 (en) 2002-10-18
US20040097514A1 (en) 2004-05-20
DK1109558T3 (da) 2002-08-26
US20020090396A1 (en) 2002-07-11
JP2006096757A (ja) 2006-04-13
EP1096937A2 (en) 2001-05-09
HU224215B1 (hu) 2005-06-28
TR200101261T2 (tr) 2002-05-21
AU6142599A (en) 2000-03-27
IL141892A0 (en) 2002-03-10
WO2000013687A3 (en) 2000-06-29
US6503911B2 (en) 2003-01-07
DE122008000065I1 (de) 2009-04-09
UA67793C2 (uk) 2004-07-15
EP1109558B1 (en) 2002-05-22
US6525057B2 (en) 2003-02-25
JP2002524416A (ja) 2002-08-06
HUP0103844A3 (en) 2002-11-28
CZ301341B6 (cs) 2010-01-20
CY2008020I1 (el) 2010-07-28
NO319434B1 (no) 2005-08-15
TR200101262T2 (tr) 2001-12-21
US20030166659A1 (en) 2003-09-04
HUP0104088A3 (en) 2002-12-28
HUP0104088A2 (hu) 2002-05-29
FR09C0001I2 (en, 2012) 2009-12-18
FR09C0001I1 (en, 2012) 2009-02-27
CN1354665A (zh) 2002-06-19
US20020004506A1 (en) 2002-01-10
CA2342390A1 (en) 2000-03-16
NZ510384A (en) 2002-10-25
RU2214233C2 (ru) 2003-10-20
IL180864A0 (en) 2007-07-04
NO20011192L (no) 2001-04-30
IL141892A (en) 2006-08-20
TWI241911B (en) 2005-10-21
AR053440A2 (es) 2007-05-09
AR022085A1 (es) 2002-09-04
NO20054324L (no) 2001-04-30
IL141893A (en) 2008-08-07
NL300371I2 (nl) 2009-10-01
AU2008207703A1 (en) 2008-09-25
MXPA01002599A (es) 2005-02-17
US6620814B2 (en) 2003-09-16
AU6036499A (en) 2000-03-27
EP1527779A1 (en) 2005-05-04
ATE285774T1 (de) 2005-01-15
US20050059667A1 (en) 2005-03-17
US20030099705A1 (en) 2003-05-29
US6303607B1 (en) 2001-10-16
WO2000013686A3 (en) 2000-07-06
US20030100566A1 (en) 2003-05-29
ES2177346T3 (es) 2002-12-01
LU91504I2 (fr) 2009-02-03
ES2234302T3 (es) 2005-06-16
AU760435B2 (en) 2003-05-15
DE69922964T2 (de) 2005-12-08
PT1096937E (pt) 2005-04-29
PL202207B1 (pl) 2009-06-30
CA2343376C (en) 2007-01-09
PT1109558E (pt) 2002-10-31
LU91504I9 (en, 2012) 2019-01-02
MXPA01002598A (es) 2002-04-08
PL196263B1 (pl) 2007-12-31
PL347073A1 (en) 2002-03-11
WO2000013686A2 (en) 2000-03-16
US20050153982A1 (en) 2005-07-14
RU2207856C2 (ru) 2003-07-10
SI1096937T1 (en) 2005-04-30
HK1040060A1 (en) 2002-05-24
HUP0103844A2 (hu) 2002-04-29
SI1109558T1 (en) 2002-10-31
JP3745621B2 (ja) 2006-02-15
UA75027C2 (uk) 2006-03-15
DE69901570D1 (de) 2002-06-27
BR9913626A (pt) 2001-12-04
US6617328B2 (en) 2003-09-09
NO2009005I1 (no) 2009-03-16
EP1109558A2 (en) 2001-06-27
CN1321088A (zh) 2001-11-07
NZ510386A (en) 2003-08-29
NO20011191D0 (no) 2001-03-08
EP1096937B1 (en) 2004-12-29
CN1211086C (zh) 2005-07-20
NO20011192D0 (no) 2001-03-08
NL300371I1 (nl) 2009-02-02
WO2000013687A2 (en) 2000-03-16
CA2343376A1 (en) 2000-03-16
BR9913553A (pt) 2001-10-23
US20060147521A1 (en) 2006-07-06
CA2342390C (en) 2006-08-29
US20060217397A1 (en) 2006-09-28
CY2008020I2 (el) 2010-07-28
ATE217794T1 (de) 2002-06-15
HK1044284B (zh) 2005-07-15

Similar Documents

Publication Publication Date Title
FR09C0001I2 (en, 2012)
IN2001KO00047A (en, 2012)
JP2538259C (en, 2012)
JP2515140C (en, 2012)
IN192322B (en, 2012)
JP2544420C (en, 2012)
JP2550250C (en, 2012)
JP2593714C (en, 2012)
JP2613794C (en, 2012)
IN190968B (en, 2012)
JP2569755C (en, 2012)
CN3076811S (en, 2012)
CN3079461S (en, 2012)
CN3075297S (en, 2012)
CN3076421S (en, 2012)
CN3071793S (en, 2012)
CN3074906S (en, 2012)
CN3074693S (en, 2012)
CN3077894S (en, 2012)
CN3082698S (en, 2012)
CN3074692S (en, 2012)
CN3078571S (en, 2012)
CN3078962S (en, 2012)
CN3079173S (en, 2012)
CN3079181S (en, 2012)

Legal Events

Date Code Title Description
MK1K Patent expired